A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3000 participants.
Also called NCT07900633
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,000 participants
- Sponsor
- Registry
-
NCT07900633 -
2026-525919-14-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Brazil, Canada, China, Czechia, France, Germany, Hungary, India, Italy, Japan, Mexico, Poland, Puerto Rico, Romania, South Korea, Spain, Türkiye, Ukraine
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07900633. Randomized; double masking; primary purpose treatment. Start 2026-12 (anticipated); primary completion 2029-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
- Acronym
- ENLIGHTEN-10
- Condition
- Obesity
- Condition
- Overweight
- Condition
- Cardiovascular Diseases
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Eloralintide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct07900633- Content hash
9051759123aa390c501a311493f4698e779964c1364967ce0fc99b1e8531263b